Parkinson's disease Nervous System Diseases
Conditions
Interventions
Each participant will inhale a hydroxy gas (2-3% hydrogen gas) or placebo gas (control condition) for two hours using a nasal cannula. The order of gas inhalation (hydroxy gas or placebo gas) will be
Sponsors
University of Kent
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. All participants must have a diagnosis of PD by a Neurologist or Geriatrician. 2. All participants must be at stage 2 or stage 3 on the Hoehn and Yahr (H&Y) scale. Stage 1 is too mild and stages 4 and 5 could potentially be too severe for appropriate study participation. 3. Male or female. 4. Able to attend the School of Sport and Exercise Sciences facilities and sit for a period of two hours. 5. All participants should be stable in the past two months.
Exclusion criteria
Exclusion criteria: 1. Participants whose Parkinson’s is not controlled. 2. Participants who are at stage 1, stage 4 and stage 5 of the H&Y scale. 3. Participants who cannot consent for themselves.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive function and manual dexterity to be measured using a Purdue Pegboard Test (the three-trial administration test-retest will be used to increase reliability) at baseline, after 1 h of gas inhalation and after 2 h of gas inhalation. | — |
Secondary
| Measure | Time frame |
|---|---|
| All of the following measures will be assessed at time points of: baseline, after 1 h of gas inhalation, and after 2 h of gas inhalation: 1.Transient mood measured using a Profile of Mood States (POMS)– Short Form. 2. Visual attention measured using The Flanker Compatibility Task 3. Tremor measured using Part 3 of the Unified Parkinson's Disease Rating Scale 4. Blood markers of oxidative stress and of inflammation/neuro inflammation will measured in serum or plasma derived from venous blood samples. | — |
Countries
England, United Kingdom
Contacts
Public ContactKimberly Dargan
Outcome results
None listed